Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9359712rdf:typepubmed:Citationlld:pubmed
pubmed-article:9359712lifeskim:mentionsumls-concept:C0369083lld:lifeskim
pubmed-article:9359712lifeskim:mentionsumls-concept:C0001175lld:lifeskim
pubmed-article:9359712lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:9359712lifeskim:mentionsumls-concept:C0005768lld:lifeskim
pubmed-article:9359712lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:9359712lifeskim:mentionsumls-concept:C0035333lld:lifeskim
pubmed-article:9359712lifeskim:mentionsumls-concept:C0449864lld:lifeskim
pubmed-article:9359712lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:9359712lifeskim:mentionsumls-concept:C1516048lld:lifeskim
pubmed-article:9359712lifeskim:mentionsumls-concept:C2828008lld:lifeskim
pubmed-article:9359712lifeskim:mentionsumls-concept:C1709793lld:lifeskim
pubmed-article:9359712lifeskim:mentionsumls-concept:C0449435lld:lifeskim
pubmed-article:9359712pubmed:issue5lld:pubmed
pubmed-article:9359712pubmed:dateCreated1997-11-21lld:pubmed
pubmed-article:9359712pubmed:abstractTextCytomegalovirus (CMV) retinitis in patients infected with human immunodeficiency virus (HIV) is a significant clinical problem. Seventy-five patients with CD4 T cell counts <100/mm3 were monitored prospectively every 2 months for CMV DNA burden. The target for DNA amplification was a 162-bp fragment from the CMV immediate early gene. CMV DNA burden, at levels of > or =320 in white blood cells or > or =32 in plasma (P = .001), particularly when sustained (P = .005 and .008, respectively), distinguished patients who developed retinitis from those who remained free of disease. Progression to retinitis was not consistently accompanied by increases in CMV burden, indicating that quantitation of CMV burden beyond threshold levels is not necessary to predict risk for development of retinitis. Virus isolation from WBC, but not urine, was also significantly associated with risk for retinitis (P = .001).lld:pubmed
pubmed-article:9359712pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9359712pubmed:languageenglld:pubmed
pubmed-article:9359712pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9359712pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9359712pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9359712pubmed:statusMEDLINElld:pubmed
pubmed-article:9359712pubmed:monthNovlld:pubmed
pubmed-article:9359712pubmed:issn0022-1899lld:pubmed
pubmed-article:9359712pubmed:authorpubmed-author:MeriganT CTClld:pubmed
pubmed-article:9359712pubmed:authorpubmed-author:RasmussenLLlld:pubmed
pubmed-article:9359712pubmed:authorpubmed-author:EfronBBlld:pubmed
pubmed-article:9359712pubmed:authorpubmed-author:DowlingAAlld:pubmed
pubmed-article:9359712pubmed:authorpubmed-author:ZipetoDDlld:pubmed
pubmed-article:9359712pubmed:authorpubmed-author:WolitzR ARAlld:pubmed
pubmed-article:9359712pubmed:issnTypePrintlld:pubmed
pubmed-article:9359712pubmed:volume176lld:pubmed
pubmed-article:9359712pubmed:ownerNLMlld:pubmed
pubmed-article:9359712pubmed:authorsCompleteYlld:pubmed
pubmed-article:9359712pubmed:pagination1146-55lld:pubmed
pubmed-article:9359712pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:9359712pubmed:meshHeadingpubmed-meshheading:9359712-...lld:pubmed
pubmed-article:9359712pubmed:meshHeadingpubmed-meshheading:9359712-...lld:pubmed
pubmed-article:9359712pubmed:meshHeadingpubmed-meshheading:9359712-...lld:pubmed
pubmed-article:9359712pubmed:meshHeadingpubmed-meshheading:9359712-...lld:pubmed
pubmed-article:9359712pubmed:meshHeadingpubmed-meshheading:9359712-...lld:pubmed
pubmed-article:9359712pubmed:meshHeadingpubmed-meshheading:9359712-...lld:pubmed
pubmed-article:9359712pubmed:meshHeadingpubmed-meshheading:9359712-...lld:pubmed
pubmed-article:9359712pubmed:meshHeadingpubmed-meshheading:9359712-...lld:pubmed
pubmed-article:9359712pubmed:meshHeadingpubmed-meshheading:9359712-...lld:pubmed
pubmed-article:9359712pubmed:meshHeadingpubmed-meshheading:9359712-...lld:pubmed
pubmed-article:9359712pubmed:meshHeadingpubmed-meshheading:9359712-...lld:pubmed
pubmed-article:9359712pubmed:meshHeadingpubmed-meshheading:9359712-...lld:pubmed
pubmed-article:9359712pubmed:meshHeadingpubmed-meshheading:9359712-...lld:pubmed
pubmed-article:9359712pubmed:year1997lld:pubmed
pubmed-article:9359712pubmed:articleTitleRisk for retinitis in patients with AIDS can be assessed by quantitation of threshold levels of cytomegalovirus DNA burden in blood.lld:pubmed
pubmed-article:9359712pubmed:affiliationCenter for AIDS Research at Stanford, Department of Medicine, Stanford University, California 94305, USA.lld:pubmed
pubmed-article:9359712pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9359712pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:9359712pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9359712lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9359712lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9359712lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9359712lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9359712lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9359712lld:pubmed